Predicting long-term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly

Neurosurgery

Volumn 70, Issue 5, 2012, Pages 1106-1112

  Kim, Eui Hyun ^a,b   Oh, Min Chul ^a,b   Lee, Eun Jig ^b,c,d   Kim, Sun Ho ^a,b  

^a Yonsei University   (South Korea)

^b Pituitary Tumor Clinic   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Acromegaly; Growth hormone; Oral glucose tolerance test; Remission; Transsphenoidal approach

Indexed keywords

GROWTH HORMONE;

ACROMEGALY; ADOLESCENT; ADULT; AGED; ARTICLE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PREDICTIVE VALUE; PRIORITY JOURNAL; REMISSION; SENSITIVITY AND SPECIFICITY; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

ACROMEGALY; ADENOMA; ADOLESCENT; ADULT; AGED; CAUSALITY; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; GLUCOSE TOLERANCE TEST; GROWTH HORMONE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POSTOPERATIVE CARE; PREVALENCE; PROGNOSIS; REMISSION INDUCTION; REPRODUCIBILITY OF RESULTS; REPUBLIC OF KOREA; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84860313461     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/NEU.0b013e31823f5c16     Document Type: Article

References (26)

1. Baris D, Gridley G, Ron E, et al. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control. 2002;13(5):395-400. (Pubitemid 34666594)
2. Bynke O, Karlberg BE, Kågedal B, Nilsson OR. Early post-operative growth hormone levels predict the result of transsphenoidal tumour removal in acromegaly. Acta Endocrinol (Copenh). 1983;103(2):158-162. (Pubitemid 13093813)
3. Melmed S. Medical progress: acromegaly. N Engl J Med. 2006;355(24): 2558-2573.
4. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf). 1994; 41(1):95-102. (Pubitemid 24232533)
5. Webb SM, Casanueva F, Wass JA. Oncological complications of excess GH in acromegaly. Pituitary. 2002;5(1):21-25. (Pubitemid 36267050)
6. Kreutzer J, Vance ML, Lopes MB, Laws ER Jr. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab. 2001;86(9):4072-4077. (Pubitemid 32848515)
7. Kristof RA, Neuloh G, Redel L, Klingmüller D, Schramm J. Reliability of the oral glucose tolerance test in the early postoperative assessment of acromegaly remission. J Neurosurg. 2002;97(6):1282-1286. (Pubitemid 35424281)
8. Minniti G, Jaffrain-Rea ML, Esposito V, Santoro A, Tamburrano G, Cantore G. Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature. Endocr Relat Cancer. 2003;10(4):611-619. (Pubitemid 38094895)
9. Ronchi CL, Arosio M, Rizzo E, Lania AG, Beck-Peccoz P, Spada A. Adequacy of current postglucose GH nadir limit (, 1 microg/l) to define long-lasting remission of acromegalic disease. Clin Endocrinol (Oxf). 2007;66(4):538-542. (Pubitemid 46434936)
10. Ronchi CL, Varca V, Giavoli C, et al. Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria. J Clin Endocrinol Metab. 2005;90(3):1377-1382. (Pubitemid 40463992)
11. Giustina A, Chanson P, Bronstein M, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95(7):3141-3148.
12. Kurosaki M, Luedecke DK, Abe T. Effectiveness of secondary transnasal surgery in GH-secreting pituitary macroadenomas. Endocr J. 2003;50(5):635-642. (Pubitemid 37442840)
13. Lüdecke DK. Recent developments in the treatment of acromegaly. Neurosurg Rev. 1985;8(3-4):167-173.
14. Ludecke DK, Abe T. Transsphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1,000 operations. Neuroendocrinology. 2006;83(3-4):230-239. (Pubitemid 44578877)
15. Valdemarsson S, Ljunggren S, Bramnert M, Norrhamn O, Nordström CH. Early postoperative growth hormone levels: high predictive value for long-term outcome after surgery for acromegaly. J Intern Med. 2000;247(6):640-650. (Pubitemid 30430340)
16. Yamada S, Shishiba Y, Kitano M, et al. Decrease in human growth hormone (HGH) levels during transsphenoidal surgery for acromegaly as a guide for prognosis. Endocrinol Jpn. 1985;32(6):899-906. (Pubitemid 16081979)
17. Lee EJ, Ahn JY, Noh T, Kim SH, Kim TS. Tumor tissue identification in the pseudocapsule of pituitary adenoma: should the pseudocapsule be removed for total resection of pituitary adenoma? Neurosurgery. 2009;64(3 suppl):62-69.
18. Damjanovic SS, Neskovic AN, Petakov MS, et al. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure? Clin Endocrinol (Oxf). 2005;62(4):410-417.
19. Freda PU. Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant? Clin Endocrinol (Oxf). 2009;71(12):166-170.
20. Freda PU, Landman RE, Sundeen RE, Post KD. Gender and age in the biochemical assessment of cure of acromegaly. Pituitary. 2001;4(3):163-171. (Pubitemid 34679332)
21. Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE, Post KD. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab. 2004;89(2):495-500. (Pubitemid 38269847)
22. Freda PU, Post KD, Powell JS, Wardlaw SL. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab. 1998;83(11):3808-3816. (Pubitemid 28513555)
23. Freda PU. Pitfalls in the biochemical assessment of acromegaly. Pituitary. 2003;6 (3):135-140. (Pubitemid 38159561)
24. Feelders R, Bidlingmaier M, Strasburger CJ, et al. Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. J Clin Endocrinol Metab. 2005;90 (12):6480-6489. (Pubitemid 41759303)
25. Berg C, Meinel T, Lahner H, Mann K, Petersenn S. Recovery of pituitary function in the late-postoperative phase after pituitary surgery: results of dynamic testing in patients with pituitary disease by insulin tolerance test 3 and 12 months after surgery. Eur J Endocrinol. 2010; 162(5) 853-859.
26. Lissett C, Shalet S. Management of pituitary tumours: strategy for investigation and follow-up. Horm Res. 2000;53(suppl 3):65-70.